ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.36 USD
+0.41 (0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.26 -0.10 (-0.15%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ANIP 65.36 +0.41(0.63%)
Will ANIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIP
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Other News for ANIP
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals Financial Report: Key Insights Revealed
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
ANI Pharmaceuticals announces launch of Baclofen Oral Suspension